CTC
ANIP icon

Central Trust Company’s ANI Pharmaceuticals ANIP Stock Holding History

Central Trust Company’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-75
Closed -$3K – 1045
2020
Q1 		$3K Sell
75
-10
-12% -$532 ﹤0.01% 1023
2019
Q4 		$5K Sell
85
-12
-12% -$795 ﹤0.01% 1053
2019
Q3 		$7K Sell
97
-19
-16% -$1.42K ﹤0.01% 952
2019
Q2 		$9K Sell
116
-20
-15% -$1.42K ﹤0.01% 935
2019
Q1 		$10K Sell
136
-30
-18% -$1.76K ﹤0.01% 875
2018
Q4 		$7K Sell
166
-20
-11% -$1.05K ﹤0.01% 965
2018
Q3 		$11K Buy
186
+30
+19% +$1.84K ﹤0.01% 967
2018
Q2 		$10K Hold
156
– – ﹤0.01% 973
2018
Q1 		$9K Buy
+156
New +$9.9K ﹤0.01% 994
2017
Q2 		– Sell
-785
Closed -$39K – 1238
2017
Q1 		$39K Buy
785
+165
+27% +$9.26K ﹤0.01% 778
2016
Q4 		$38K Sell
620
-95
-13% -$5.81K ﹤0.01% 766
2016
Q3 		$47K Buy
+715
New +$44.7K ﹤0.01% 695

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Central Trust Company's ANIP Position: Q2 2020 in Review

Central Trust Company sold out of ANI Pharmaceuticals (ANIP) in Q2 2020, closing a stake of 75 shares — an estimated $3K sold.

Central Trust Company first reported a position in ANIP in Q3 2016 and held it in 12 quarters. The position peaked at $47K in Q3 2016. 134 funds tracked by Wall St. Rank hold ANIP as of Q2 2020.

  • Central Trust Company reported no remaining ANI Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Central Trust Company sold 75 ANI Pharmaceuticals shares in Q2 2020, an estimated $3K.
  • Central Trust Company first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 12 quarters.
  • Central Trust Company's ANI Pharmaceuticals position peaked at $47K in Q3 2016.
  • 134 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2020.

Based on Central Trust Company's 13F filing for Q2 2020, filed 14 Jul 2020.